Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680560 · ClinicalTrials.gov registry record · Phase 1
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
A Phase 1 study, sponsored by Cogent Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03680560: Clinical Trial Phase 1 study, sponsored by Cogent Biosciences.
NCT03680560 is a Phase 1 study that was terminated before completion, run by Cogent Biosciences. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680560, a Phase 1 study, was terminated before completion, sponsored by Cogent Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Interventions
- DRUG Trastuzumab
- BIOLOGICAL ACTR T Cell Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 1 |
Why NCT03680560 stopped before completion
NCT03680560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT03680560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03680560 about?
NCT03680560 is a clinical study titled "Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers". This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
What is the current status of trial NCT03680560?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-03-13. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT03680560?
The interventions under investigation include: Trastuzumab (DRUG), ACTR T Cell Product (BIOLOGICAL).
Who is sponsoring clinical trial NCT03680560?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03680560's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI